Figure 2 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma

Figure 2 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma

<p><i>In vivo</i> CRISPR-Cas9 screening identifies transforming mutations that interact with mutant Ras. <b>A,</b> Schematic of this study in which high-content sequencing data are collated from patients with ICC and the mutational profile of these tumors rationalized t...

Повний опис

Збережено в:

Бібліографічні деталі
Автор:	Nicholas T. Younger (14956251) (author)
Інші автори:	Mollie L. Wilson (14956254) (author), Anabel Martinez Lyons (14956257) (author), Edward J. Jarman (9773166) (author), Alison M. Meynert (14956260) (author), Graeme R. Grimes (14160170) (author), Konstantinos Gournopanos (14956263) (author), Scott H. Waddell (14956266) (author), Peter A. Tennant (14956269) (author), David H. Wilson (14956272) (author), Rachel V. Guest (14956275) (author), Stephen J. Wigmore (14915943) (author), Juan Carlos Acosta (14956278) (author), Timothy J. Kendall (14956281) (author), Martin S. Taylor (14956284) (author), Duncan Sproul (13971883) (author), Pleasantine Mill (256953) (author), Luke Boulter (14956287) (author)
Опубліковано:	2025
Предмети:	Cancer Cancer Biology Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Cell Signaling Computational Methods Sequence analysis Drug Targets Gastrointestinal Cancers Liver cancer Gene Technologies Comparative genomics Oncogenes & Tumor Suppressors Kras Preclinical Models Animal models of cancer
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси

Figure 1 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
за авторством: Nicholas T. Younger (14956251)
Опубліковано: (2025)

Figure 3 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
за авторством: Nicholas T. Younger (14956251)
Опубліковано: (2025)

Figure 4 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
за авторством: Nicholas T. Younger (14956251)
Опубліковано: (2025)

Supplementary Table S1 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
за авторством: Queralt Serra-Camprubí (15050174)
Опубліковано: (2025)

Supplementary Table S2 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
за авторством: Queralt Serra-Camprubí (15050174)
Опубліковано: (2025)

Supplementary Table S3 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
за авторством: Queralt Serra-Camprubí (15050174)
Опубліковано: (2025)

Supplementary Table S4 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
за авторством: Queralt Serra-Camprubí (15050174)
Опубліковано: (2025)

Supplementary Table S5 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
за авторством: Queralt Serra-Camprubí (15050174)
Опубліковано: (2025)

Supplementary Tables from <i>In Vivo</i> Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
за авторством: Elisa ten Hacken (15136187)
Опубліковано: (2025)

Figure 1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
за авторством: Ernesto Gargiulo (15134961)
Опубліковано: (2025)

Figure 2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
за авторством: Ernesto Gargiulo (15134961)
Опубліковано: (2025)

Figure 3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
за авторством: Ernesto Gargiulo (15134961)
Опубліковано: (2025)

Figure 4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
за авторством: Ernesto Gargiulo (15134961)
Опубліковано: (2025)

Figure 5 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
за авторством: Ernesto Gargiulo (15134961)
Опубліковано: (2025)

Figure 6 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
за авторством: Ernesto Gargiulo (15134961)
Опубліковано: (2025)

Figure 7 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
за авторством: Ernesto Gargiulo (15134961)
Опубліковано: (2025)

Supplementary Table S1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
за авторством: Ernesto Gargiulo (15134961)
Опубліковано: (2025)

Supplementary Table S2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
за авторством: Ernesto Gargiulo (15134961)
Опубліковано: (2025)

Supplementary Table S3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
за авторством: Ernesto Gargiulo (15134961)
Опубліковано: (2025)

Supplementary Table S4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
за авторством: Ernesto Gargiulo (15134961)
Опубліковано: (2025)

Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
за авторством: Ana Vujovic (15207479)
Опубліковано: (2025)

Supplementary Table S2 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
за авторством: Ana Vujovic (15207479)
Опубліковано: (2025)

Supplementary Table S3 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
за авторством: Ana Vujovic (15207479)
Опубліковано: (2025)

Supplementary Table S4 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
за авторством: Ana Vujovic (15207479)
Опубліковано: (2025)

Supplementary Table S5 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
за авторством: Ana Vujovic (15207479)
Опубліковано: (2025)

Supplementary Table S6 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
за авторством: Ana Vujovic (15207479)
Опубліковано: (2025)

Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
за авторством: Ana Vujovic (15207479)
Опубліковано: (2025)

Supplementary Table S8 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
за авторством: Ana Vujovic (15207479)
Опубліковано: (2025)

Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
за авторством: Ana Vujovic (15207479)
Опубліковано: (2025)

Table 1 from Addressing Common Misuses and Pitfalls of <i>P</i> values in Biomedical Research
за авторством: Ming Wang (8809334)
Опубліковано: (2025)

Supplementary Tables from Biallelic <i>Dicer1</i> Mutations in the Gynecologic Tract of Mice Drive Lineage-Specific Development of <i>DICER1</i> Syndrome–Associated Cancer
за авторством: Yemin Wang (17315078)
Опубліковано: (2025)

Supplementary Table S3 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
за авторством: Caleb N. Seavey (15056489)
Опубліковано: (2025)

Supplementary Table S4 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
за авторством: Caleb N. Seavey (15056489)
Опубліковано: (2025)

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
за авторством: Yuncheng Bei (16546095)
Опубліковано: (2025)

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
за авторством: Yuncheng Bei (16546095)
Опубліковано: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
за авторством: Yuncheng Bei (16546095)
Опубліковано: (2025)

Table S9 from Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer
за авторством: Zhihang Chen (17315678)
Опубліковано: (2025)

Supplementary Data from Genetic Modulation of <i>BET1L</i> Confers Colorectal Cancer Susceptibility by Reducing miRNA Binding and m<sup>6</sup>A Modification
за авторством: Shuwei Li (16437116)
Опубліковано: (2025)

Figure S1 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
за авторством: Subhamoy Chakraborty (16648124)
Опубліковано: (2025)

Figure S2 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
за авторством: Subhamoy Chakraborty (16648124)
Опубліковано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_vfhmiukhlpo1386gn4sku0bqmm